ABOUT HEARTSINE®

Company

HeartSine® was founded in 1997 for the purpose of developing a family of products focused on an emerging growth segment of the medical device marketplace: easy-to-use, affordable defibrillators for the home and public access markets. HeartSine® established R&D activities in Northern Ireland and initiated a formal collaboration with the University of Ulster's Bioengineering Center (NIBEC) and its partner, the Royal Victoria (RVH), a local teaching and research hospital, to augment and enhance our in-house development activities. HeartSine's engineering team has focused on developing leading edge, innovative technology systems for defibrillators.

HeartSine's technology and innovation is based on a proven history of development in the field of cardiac defibrillation that began in the 1960s. (See History for further historical background). Our R&D is spearheaded by the best technology experts in the industry. Our Chief Technology Officer is Professor John Anderson who was pivotal in the groundbreaking work that created the world's first mobile coronary care unit. Professor Anderson has been miniaturizing defibrillators for four decades. He has been a cornerstone in developing HeartSine's state-of-the-art samaritan®PAD Public Access Defibrillator. Also steering our research is a leading authority in the field of clinical cardiac research, Dr. Jennifer Adgey, (see Management Team and Medical Advisory Board for more background details).

Our core technologies include:

• Cardiac defibrillation, pacing and cardioversion
• SCOPE™ Biphasic waveform technology
• Arrhythmia detection
• Diagnostic algorithms
• Innovative sensor technology
• Defibrillator electrode technologies

HeartSine's focus is to design the best defibrillators possible to address the unique needs for the public access and consumer market. (See Mission for more.)